AtaiBeckley is in structured discussions with pharma companies and royalty investors about a potential partnership for its lead candidate, intranasal 5-MeO-DMT (BPL-003) for treatment-resistant depression (TRD), sources close to the company told Psychedelic Alpha. The talks, first reported by Bloomberg on Saturday, are being advised by Jefferies, JP Morgan, and TD Cowen, and could conclude as…
